- $136.04m
- $29.19m
- $33.03m
MaxCyte, Inc. MaxCyte, Inc. - MXCR - MaxCyte Appoints Cynthia Collins to Board
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Notice of Results
MaxCyte, Inc. MaxCyte, Inc. - MXCR - MaxCyte Appoints Ali Soleymannezhad as CCO
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Exercise of options and PDMR dealing
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Exercise of options and PDMR dealing
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
Brief: Maxcyte Signs Strategic Platform License
MaxCyte, Inc. MaxCyte, Inc. - MXCR - TR-1: Notification of major holdings
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Signing of Strategic Platform License
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Exercise of options and PDMR dealing
RCS - MaxCyte, Inc. - Bioprocessing Conference Participation
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Exercise of options and PDMR dealing
Brief: Maxcyte Inc Says Confident In Full Year Guidance
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Second Quarter and Half-Year Results
MaxCyte Inc reports results for the quarter ended in June - Earnings Summary
Brief: MaxCyte Q2 Revenue USD 10.4 Million Vs. IBES Estimate USD 7.92 Million
MaxCyte Inc expected to post a loss of 13 cents a share - Earnings Preview